Infantile hypertrophic pyloric stenosis: maternal diabetes and perinatal exposure to non-macrolide antibiotics.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
11
11
2022
accepted:
17
01
2023
revised:
07
01
2023
medline:
10
4
2023
pubmed:
27
1
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Infant exposure to macrolide antibiotics is a risk factor for infantile hypertrophic pyloric stenosis (IHPS). The aim of the study was to establish whether perinatal exposure to non-macrolide antibiotics was a risk factor for IHPS. A retrospective matched case-control study was performed using a database including all children born at Soroka University Medical Centre between 2006 and 2018. Cases and controls were compared using Student T-test and multiple logistic regression. Of 189 461 children in the database, 63 infants were diagnosed with IHPS and underwent pyloromyotomy. There was no association between non-macrolide antibiotic exposure and IHPS. Maternal diabetes (DM) had an adjusted odds ratio for infants developing IHPS of 4.53 (p = 0.004). The lack of association between exposure to non-macrolide antibiotics and IHPS suggests a quality unique to macrolides. An association between DM and IHPS may suggest elevated levels of IGF-1 have a role.
Identifiants
pubmed: 36702873
doi: 10.1038/s41372-023-01619-2
pii: 10.1038/s41372-023-01619-2
doi:
Substances chimiques
Anti-Bacterial Agents
0
Macrolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-469Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Svenningsson A, Svensson T, Akre O, Nordenskjöld A. Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis. J Pediatr Surg. 2014;49:1226–31.
doi: 10.1016/j.jpedsurg.2014.01.053
pubmed: 25092081
Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: Nationwide cohort study. BMJ 2014;348:g1908.
doi: 10.1136/bmj.g1908
pubmed: 24618148
pmcid: 3949411
Krogh C, Biggar RJ, Fischer TK, Lindholm M, Wohlfahrt J, Melbye M. Bottle-feeding and the risk of pyloric stenosis. Pediatrics 2012;130:e943.
doi: 10.1542/peds.2011-2785
pubmed: 22945411
pmcid: 3457615
Krogh C, Gørtz S, Wohlfahrt J, Biggar RJ, Melbye M, Fischer TK. Pre-and perinatal risk factors for pyloric stenosis and their influence on the male predominance. Am J Epidemiol. 2012;176:24–31.
doi: 10.1093/aje/kwr493
pubmed: 22553083
Murchison L, De Coppi P, Eaton S. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: A systematic review and meta-analysis. Pediatr Surg Int. 2016;32:1147–52.
doi: 10.1007/s00383-016-3971-5
pubmed: 27655365
pmcid: 5106491
Leppälehto E, Pärtty A, Kalliomäki M, Löyttyniemi E, Isolauri E, Rautava S. Maternal intrapartum antibiotic administration and infantile colic: Is there a connection? Neonatology 2018;114:226–9.
doi: 10.1159/000489991
pubmed: 29940563
Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017;66:515–22.
doi: 10.1016/j.alit.2017.07.010
pubmed: 28826938
Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139:380–4.
doi: 10.1067/mpd.2001.117577
pubmed: 11562617
Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: A prospective cohort study. BJOG: Int J Obstet Gynaecol. 2016;123:983–93.
doi: 10.1111/1471-0528.13601
El-Gohary Y, Abdelhafeez A, Paton E, Gosain A, Murphy A. Pyloric stenosis: An enigma more than a century after the first successful treatment. Pediatr Surg Int. 2018;34:21–7.
doi: 10.1007/s00383-017-4196-y
pubmed: 29030700
Ericson J, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, et al. Use and safety of erythromycin and metoclopramide in hospitalized infants. J Pediatr Gastroenterol Nutr. 2015;61:334–9.
doi: 10.1097/MPG.0000000000000792
pubmed: 25806675
pmcid: 4553109
Pezzati M, Dani C, Biadaioli R, Gambi B, Lachina L, Rubaltelli F. Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants. Eur J Pediatr. 2001;160:572–5.
doi: 10.1007/s004310100794
pubmed: 11585082
Riskin A, Itzchaki O, Bader D, Iofe A, Toropine A, Riskin-Mashiah S. Perinatal outcomes in infants of mothers with diabetes in pregnancy. Isr Med Assoc J. 2020;22:569–75.
pubmed: 33236556
Depla AL, De Wit L, Steenhuis TJ, Slieker MG, Voormolen DN, Scheffer PG, et al. Effect of maternal diabetes on fetal heart function on echocardiography: Systematic review and meta‐analysis. Ultrasound Obstet Gynecol. 2021;57:539–50.
doi: 10.1002/uog.22163
pubmed: 32730637
pmcid: 8048940
Kuemmerle JF, Zhou H, Bowers JG. IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins. Am J Physiol - Gastrointest Liver Physiol. 2004;286:412–9.
doi: 10.1152/ajpgi.00403.2003
Jabłoński J, Gawrońska R, Gawłowska A, Kobos J, Andrzejewska E. Study of insulin-like growth factor-1 (IGF-1) and platelet-derived endothelial cell growth factor (PDEGF) expression in children with infantile hypertrophic pyloric stenosis. Med Sci Monit. 2006;12:CR27–CR30.
pubmed: 16369467
Fang X-S, Zhang M-S, Guo J-Y, Zheng J. Effects of insulin-like growth factor-1 on endoplasmic reticulum stress and autophagy in rat smooth muscle cells at different glucose concentrations in vitro. Mol Cell Biochem. 2019;451:11–20.
doi: 10.1007/s11010-018-3388-7
pubmed: 30008033